secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001493152-23-016177
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q1 net loss $4.0M, cash $1.7M; secures additional $3M debt from WFIA
------------------------------------------------------------------------------

- Net loss $4.0M for Q1 2023, improved from $5.0M in Q1 2022; R&D expenses $2.1M (down 25% YoY).
- Cash and equivalents $1.7M at March 31, 2023; expects funding into Q3 2023 with new $3M debt.
- Received $3M additional debt from WFIA, increasing promissory note to $8M, unsecured at 15% interest, due Aug 2025.
- Completed transfer of PTR manufacturing to Societal CDMO; Phase 3 adult dose-optimization results expected Q3 2023.
- Entered joint commercialization agreement with Indegene for CTx-1301 upon FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer